Efficacy and Safety of Intermittent Repeated Levosimendan Infusions in Advanced Heart Failure Patients: The LAICA Study

In our study, intermittent levosimendan in patients with AdHF produced a statistically non-significant reduction in the incidence of hospital readmissions for acute decompensated HF, a significantly lower cumulative incidence of acute decompensation of HF and/or death at 1 and 3 month of treatment and a significant improvement in survival during 12 months of treatment.